These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15845425)

  • 21. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
    Zhang Z; Diener RM; Lipman JM
    Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
    Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
    Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
    Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
    Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
    Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.
    Paterson DL; David K; Mrsic M; Cetkovsky P; Weng XH; Sterba J; Krivan G; Boskovic D; Lu M; Zhu LP;
    J Antimicrob Chemother; 2008 Dec; 62(6):1392-400. PubMed ID: 18812423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.
    Wingard JR; Kubilis P; Lee L; Yee G; White M; Walshe L; Bowden R; Anaissie E; Hiemenz J; Lister J
    Clin Infect Dis; 1999 Dec; 29(6):1402-7. PubMed ID: 10585786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex.
    Kline S; Larsen TA; Fieber L; Fishbach R; Greenwood M; Harris R; Kline MW; Tennican PO; Janoff EN
    Clin Infect Dis; 1995 Nov; 21(5):1154-8. PubMed ID: 8589135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
    Walsh TJ; Hiemenz JW; Seibel NL; Perfect JR; Horwith G; Lee L; Silber JL; DiNubile MJ; Reboli A; Bow E; Lister J; Anaissie EJ
    Clin Infect Dis; 1998 Jun; 26(6):1383-96. PubMed ID: 9636868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
    Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
    Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan.
    Chen CY; Kumar RN; Feng YH; Ho CH; You JY; Liao CC; Tseng CH; Mavros P; Gerth WC; Chen YC
    J Antimicrob Chemother; 2006 Jun; 57(6):1181-8. PubMed ID: 16595642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
    Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
    Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
    Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
    Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
    Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
    Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis.
    Baddour LM; Perfect JR; Ostrosky-Zeichner L
    Clin Infect Dis; 2005 May; 40 Suppl 6():S409-13. PubMed ID: 15809927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
    Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
    Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation.
    Kolve H; Ahlke E; Fegeler W; Ritter J; Jürgens H; Groll AH
    J Antimicrob Chemother; 2009 Aug; 64(2):383-7. PubMed ID: 19491205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
    Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
    Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections.
    Linden P; Lee L; Walsh TJ
    Pharmacotherapy; 1999 Nov; 19(11):1261-8. PubMed ID: 10555932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.